Frederick F. Lang

Surgical resection of intrinsic insular tumors: complication avoidance.

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.

Prospective clinical trials of brain tumor therapy: the critical role of neurosurgeons.

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.

Diffusely infiltrative low-grade gliomas in adults.

Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death.

Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide.

High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors.

Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas.

REST regulates oncogenic properties of glioblastoma stem cells.

TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells.

A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors.

miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.

A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.

Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery.

Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma.

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

A history of the AANS/CNS Section on Tumors Biennial Satellite Symposium.

FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints.

ESI-MS/MS and MALDI-IMS Localization Reveal Alterations in Phosphatidic Acid, Diacylglycerol, and DHA in Glioma Stem Cell Xenografts.

Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.

Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.

Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.

A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.

TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1.

Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.

Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.

Ionizing radiation augments glioma tropism of mesenchymal stem cells.

Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.

Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.

TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation.

Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587.

Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas.

Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection.

A gene expression signature predicts recurrence-free survival in meningioma.

MRI venous architecture of insula.

A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models.

Distinct mechanisms enable inward or outward budding from late endosomes/multivesicular bodies.

Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes.

REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.

Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era.

Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.

Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells.

GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory.

Advances in endovascular neuro-oncology: endovascular selective intra-arterial (ESIA) infusion of targeted biologic therapy for brain tumors.

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment.

Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.

A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.

The role of resting-state functional MRI for clinical preoperative language mapping.

Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration.

Impact of anesthesia and analgesia techniques on glioblastoma progression. A narrative review.

Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors.

RNAi technology targeting the fusion breakpoint: an opportunity for precision medicine.

Considerations for designing preclinical cancer immune nanomedicine studies.

Intraarterial delivery of virotherapy for glioblastoma.

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations.

The history of neurosurgery at Baylor College of Medicine.

Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma.

An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.

Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells.

Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses.

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.

Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma.

Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance.

Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells.

Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors.

Circumferential sulcus-guided resection technique for improved outcomes of low-grade gliomas.

Long term outcomes following surgery for pineal region tumors.

Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target.

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.

Preclinical animal brain tumor models for interventional neuro-oncology.

A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry.

NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors.

Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.

Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles.

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.

Multiomics analyses reveal /YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance.

Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.

Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma.

Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer.

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy.

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.

The genomic alterations in glioblastoma influence the levels of CSF metabolites.

Collision tumor: Multinodular and vacuolating neuronal tumor with isocitrate dehydrogenase-mutant diffuse astrocytoma.